Recently, we reported the synergistic anti-tumor effects of an anti-TS peptide in association with some chemotherapeutics and delivered into cells both via the SAINT-PhD delivery system and via pH-sensitive pegylated liposomes (Edwards et al., 2015). Here, TYMS is linked to neoplasm.